Bilateral Renal Tumour As Indicator for Birt-hogg-dubé Syndrome

Overview

Journal Case Rep Med

Publisher Wiley

Specialty General Medicine

Date 2014 Apr 29

PMID 24772173

Authors

P C Johannesma

R J A van Moorselaar

S Horenblas

L E van der Kolk

E Thunnissen

J H T M van Waesberghe

F H Menko

P E Postmus

Affiliations

Soon will be listed here.

Abstract

Birt-Hogg-Dubé (BHD) syndrome is a cancer disorder caused by a pathogenic FLCN mutation characterized by fibrofolliculomas, lung cysts, pneumothorax, benign renal cyst, and renal cell carcinoma (RCC). In this case we describe a patient with bilateral renal tumour and a positive familial history for pneumothorax and renal cancer. Based on this clinical presentation, the patient was suspected for BHD syndrome, which was confirmed after molecular testing. We discuss the importance of recognizing this autosomal dominant cancer disorder when a patient is presented at the urologist with a positive family history of chromophobe renal cell cancer or a positive familial history for renal cell cancer and pneumothorax.

References

Houweling A, Gijezen L, Jonker M, van Doorn M, Oldenburg R, van Spaendonck-Zwarts K . Renal cancer and pneumothorax risk in Birt-Hogg-Dubé syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families. Br J Cancer. 2011; 105(12):1912-9. PMC: 3251884. DOI: 10.1038/bjc.2011.463. View

Menko F, van Steensel M, Giraud S, Friis-Hansen L, Richard S, Ungari S . Birt-Hogg-Dubé syndrome: diagnosis and management. Lancet Oncol. 2009; 10(12):1199-206. DOI: 10.1016/S1470-2045(09)70188-3. View

Toro J, Pautler S, Stewart L, Glenn G, Weinreich M, Toure O . Lung cysts, spontaneous pneumothorax, and genetic associations in 89 families with Birt-Hogg-Dubé syndrome. Am J Respir Crit Care Med. 2007; 175(10):1044-53. PMC: 1899269. DOI: 10.1164/rccm.200610-1483OC. View

Kluijt I, de Jong D, Teertstra H, Axwijk P, Gille J, Bell K . Early onset of renal cancer in a family with Birt-Hogg-Dubé syndrome. Clin Genet. 2009; 75(6):537-43. DOI: 10.1111/j.1399-0004.2009.01159.x. View

Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2011; 127(12):2893-917. DOI: 10.1002/ijc.25516. View

Pavlovich C, Grubb 3rd R, Hurley K, Glenn G, Toro J, Schmidt L . Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. J Urol. 2005; 173(5):1482-6. DOI: 10.1097/01.ju.0000154629.45832.30. View

Gambichler T, Wolter M, Altmeyer P, Hoffman K . Treatment of Birt-Hogg-Dubé syndrome with erbium:YAG laser. J Am Acad Dermatol. 2000; 43(5 Pt 1):856-8. DOI: 10.1067/mjd.2000.109294. View

Stamatakis L, Metwalli A, Middelton L, Linehan W . Diagnosis and management of BHD-associated kidney cancer. Fam Cancer. 2013; 12(3):397-402. PMC: 4175415. DOI: 10.1007/s10689-013-9657-4. View

Pavlovich C, Walther M, Eyler R, Hewitt S, Zbar B, Linehan W . Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol. 2002; 26(12):1542-52. DOI: 10.1097/00000478-200212000-00002. View

10.

Khoo S, Giraud S, Kahnoski K, Chen J, Motorna O, Nickolov R . Clinical and genetic studies of Birt-Hogg-Dubé syndrome. J Med Genet. 2002; 39(12):906-12. PMC: 1757219. DOI: 10.1136/jmg.39.12.906. View

11.

Baba M, Hong S, Sharma N, Warren M, Nickerson M, Iwamatsu A . Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A. 2006; 103(42):15552-7. PMC: 1592464. DOI: 10.1073/pnas.0603781103. View